Nonhormonal menopause treatment took a visible step forward this summer. Here is what the new Phase 2 results show, what they don’t, and what employers should take from them.
For most of the last two decades, the menopause treatment conversation has been organized around a single fork in the road: hormone therapy, or manage without it. Nonhormonal menopause treatment existed at the margins, but rarely as a serious part of the conversation. That framing has shaped clinical practice, benefits design, and a great deal of unnecessary suffering.
It is starting to change. In August 2026, AbCellera announced top-line results from a Phase 2 trial of ABCL635, an investigational antibody treatment for moderate–to–severe hot flashes and night sweats associated with menopause.
A Nonhormonal Menopause Treatment That Works on the Brain
ABCL635 is a neurokinin 3 receptor (NK3R) antagonist antibody. It targets a brain pathway involved in regulating body temperature — specifically the KNDy neurons in the hypothalamus that become dysregulated as estrogen declines. It is being studied as a long-acting nonhormonal menopause treatment given by injection rather than as a daily pill.
The mechanism matters more than the headline. A nonhormonal menopause treatment changes the conversation for women who cannot take hormone therapy, choose not to, or have been told no without a real discussion.
What the Trial Reported
The randomized, double–blind, placebo–controlled Phase 2 study enrolled 92 postmenopausal women. Participants received a single 600 mg subcutaneous dose. At four weeks, according to the company’s top-line results:
- Frequency. A mean reduction from baseline of roughly 83 percent in moderate–to–severe hot flashes, compared with about 33 percent for placebo.
- Severity. A mean reduction of roughly 58 percent, compared with about 12 percent for placebo.
- Sleep and overall impression. Statistically significant improvements in sleep scores and in participants’ own assessment of change.
- Tolerability. No serious or severe adverse events, and no adverse events leading to discontinuation during the four-week assessment period.
The most common adverse events reported more frequently than with placebo were headache, fatigue, and injection–site reactions.
The Perspective That Belongs With the Numbers
Encouraging is not the same as established. ABCL635 remains investigational and has not been approved by the FDA. The trial was small. The findings come from a company announcement of top-line results rather than a complete peer-reviewed publication. Larger and longer studies will be needed to confirm effectiveness, duration of benefit, and safety.
None of that makes the result unimportant. It makes it early. Those are different things, and the difference is worth holding onto in a space where women have been handed both overstated promises and dismissive shrugs for a very long time.
Why an Employer Should Care About a Phase 2 Result
It is fair to ask why a benefits leader should track an investigational therapy. The answer is not that anyone should be recommending it. Employers have no business recommending a particular treatment.
The answer is that access to any nonhormonal menopause treatment will run through the same benefits design that already decides whether women can fill a hormone therapy prescription at all. Hot flashes and night sweats are not merely uncomfortable. When symptoms repeatedly interrupt sleep, the effect carries into the workday — in energy, concentration, attendance, and performance. The treatment landscape for those symptoms is widening, which means the gap between employees who get effective care and employees who never have the conversation is about to widen too.
What employers can do is concrete:
- Recognize menopause as a legitimate health and workforce issue rather than a private one.
- Make credible, current education available so employees are not relying on social media to learn what their options are.
- Ensure benefits design provides real access to clinicians with menopause training, who can discuss hormone therapy and nonhormonal menopause treatment with equal fluency.
- Train managers to respond to symptom-related performance shifts as a health matter, not a commitment problem.
The Direction of Travel
Menopause care is expanding beyond a binary choice, and nonhormonal menopause treatment is a large part of why. It is becoming more personalized, and potentially far more convenient. Treating menopause as a whole-person health issue means keeping pace with that. Organizations that treat that as a signal — rather than waiting for a product launch to force the issue — will be in a much better position when the options do arrive.
Turn Menopause Awareness Into Practical Support
TeltraCare helps employers translate a fast-moving clinical landscape into something employees can actually use: evidence-based education, manager and HR training, accommodation guidance, and access to specialized menopause care.
Important Note
ABCL635 is investigational and is not approved by the U.S. Food and Drug Administration. This article is for general education and is not medical advice. Decisions about menopause treatment should be made with a qualified healthcare professional.
Source: AbCellera, Phase 2 top-line results announced August 10, 2026. This post is expanded from a LinkedIn reflection by Katy Khalili, Co-Founder of TeltraCare.